Russell Lewis

Professore Associato, Malattie Infettive (MED/17)

Università degli Studi di Bari Aldo Moro Scuola di Medicina

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Microbiology Microbiology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Russell Lewis is an Associate Professor in Infectious Diseases (MED/17) at the Università degli Studi di Padova, Department of Molecular Medicine, Italy. His research primarily focuses on antifungal pharmacotherapy, including studies on echinocandins, triazole drug interactions, and novel therapeutic approaches for invasive fungal infections in immunocompromised patients. Recently, he has contributed to significant literature on the management of mucormycosis and invasive pulmonary aspergillosis, emphasizing clinical practices in antifungal prophylaxis and monitoring.

Articles (14)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Chiara Sartor

ITALY

View details

Melissa Johnson

Duke University School of Medicine

UNITED STATES

View details

Navaneeth Narayanan

Adjunct Assistant Profesor

Rutgers New Jersey Medical School

UNITED STATES

View details

Dario Cattaneo

University Hospital

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Russell Lewis

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics

Triazole antifungal drug interactions—practical considerations for excellent prescribing

The Impact of Dimitrios P. Kontoyiannis on Mucormycosis Research

Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomes

Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists

Antifungal Prophylaxis in the Era of Targeted Chemotherapy for Acute Myelogenous Leukemia

Successful Treatment of Paecilomyces variotii Pneumonia and Lupus Nephritis With Posaconazole-Cyclophosphamide Co-administration Without Drug Interaction–Induced Toxicity

Liposomal amphotericin B—the future

Quandaries of deciding when to change first-line therapy in invasive pulmonary aspergillosis

Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association

Breakthrough Mucormycosis Developing on Mucorales-Active Antifungals Portrays a Poor Prognosis in Patients with Hematologic Cancer

Ceftolozane-tazobactam treatment of hypervirulent multidrug resistant pseudomonas aeruginosa infections in neutropenic patients

Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections

Combination antifungal therapy for breakthrough invasive mould disease in patients with haematological malignancies: when management reasoning eclipses evidence-based medicine

Collaborators (4)

Chiara Sartor

Melissa Johnson

Navaneeth Narayanan

Dario Cattaneo

Make your next move.